Michael Anthony Avallone, MD
Urology · Lompoc
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 14 years
- University of Miami, Lm Miller School of Medicine, 2012
Offices
1 location · Urology Associates of the Central Coast · 13 clinicians in this group
Hospitals listed: Adventist Health Twin Cities · French Hospital Medical Center · Lompoc Valley Medical Center · Marian Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Avallone’s office at (805) 733-8150 to ask if they take your plan before you enroll.
State licence records
1 licence
- Colorado DR.58294Physician · since 2017 · expires 2019-04-30Specialty on the licence: UrologyExpiredNo board action on this licenceCheck it with the stateWhat they told the state about themselves
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health Twin CitiesTempleton, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 3 of 5 · 60% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.41, Oct 2024 – Sep 2025
- French Hospital Medical CenterSan Luis Obispo, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.23, Oct 2024 – Sep 2025
- Lompoc Valley Medical CenterLompoc, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPatients rate it 2 of 5 · 45% would definitely recommend itOverall rating: 1 of 5 starsNo measure marked better or worse than the national rate
- Marian Regional Medical CenterSanta Maria, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 68% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.37 to 0.96), Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.081, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health Twin Cities
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 0 better, 5 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.41 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 359 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.94 (0.51 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 66 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.7 · 198 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.6 · 335 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.9 · 113 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 1,156 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.48) · 2,873 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.08 to 0.5) · 2,701 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.28 (1.85 to 6.72) · 375 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.53 (0.84 to 4.22) · 371 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.14 (0 to 19.18) · 39 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.21 (0.88 to 9.54) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 97 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 2,369 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 41 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.704 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 40.3 · 216 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 6.5 · 313 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.5 · 39 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.9 · 69 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (10.4 to 18.7) · 246 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.4) · 220 cases | No different | Jan 2024 – Dec 2024 |
What patients said (555 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 35% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for French Hospital Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.23 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.89 (0 to 1.89) · 660 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.71 (0.39 to 1.04) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 154.33 (99.56 to 209.1) · 63 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.9 · 56 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.3 · 273 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.7 · 355 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 275 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.5 · 69 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 1,569 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 4,085 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,358 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 1,221 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.97 (0.47 to 3.48) · 567 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.54 (1.03 to 4.05) · 1,101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.3 (0.36 to 12.23) · 585 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.66 (0.03 to 7.29) · 576 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.98 (0.5 to 3.47) · 185 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.96) · 3,231 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 53 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 2.935 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 252 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 330 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -2.9 · 296 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -8.5 · 382 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2 · 272 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.7 (6.5 to 14.1) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 40 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10 · 77 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.7 (8.9 to 15.1) · 837 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 706 cases | No different | Jan 2024 – Dec 2024 |
What patients said (706 patients answered, 28% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 5 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 33% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Lompoc Valley Medical Center
Behind the star rating — Deaths: 0 better, 3 the same, 2 worse of 5 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.76 (0.72 to 2.79) · 397 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.01 (0.57 to 1.46) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 10.6 · 53 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.6 · 83 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 21.1 · 166 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.4 · 46 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5.1 · 470 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,795 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,747 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.06 (0.59 to 5.53) · 334 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 194 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.5 (0.82 to 4.18) · 327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.15 (3.05 to 21.25) · 190 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.54 (1.44 to 9.65) · 172 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.23) · 129 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.5) · 1,468 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.1 · 30 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.608 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.782 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.8 · 69 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 5.8 · 88 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 82.8 · 147 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.6 · 119 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.2 to 7.7) · 58 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.6 to 15.1) · 58 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.7 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 30 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.8 to 16.9) · 1,023 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 73 cases | No different | Jan 2024 – Dec 2024 |
What patients said (182 patients answered, 14% of those asked)
| Cleanliness | 4 |
| Nurse communication | 1 |
| Doctor communication | 2 |
| Communication about medicines | 1 |
| Discharge information | 3 |
| Overall hospital rating | 1 |
| Quietness | 1 |
| Recommend hospital | 1 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 66% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 47% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 64% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 46% |
| Staff "always" explained new medications | 63% |
| Nurses "always" explained things so they could understand | 60% |
| Nurses "always" listened carefully | 64% |
| Nurses "always" treated them with courtesy and respect | 75% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 45% |
| Staff "always" explained possible side effects | 31% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Marian Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.67 (0.37 to 0.96) | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.081 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0.06 to 1.93) · 1,191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 189.73 (139.29 to 240.17) · 66 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.7 · 103 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 15.9 · 247 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 478 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 470 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 237 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 3,050 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 8,823 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.42) · 8,672 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.87 (0.97 to 4.76) · 2,024 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.12 (0.57 to 3.67) · 782 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.29 (0.85 to 3.72) · 1,934 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 3.63 (0 to 9.97) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.01 (1.37 to 8.65) · 748 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.88 (0.43 to 3.32) · 373 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.13 (0 to 0.73) · 6,968 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 179 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.245 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.85 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.952 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.687 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 198 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.8 · 232 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.8 · 541 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8.6 · 473 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 434 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.6 (5 to 8.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.9 (8.8 to 13.4) · 519 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.3 · 83 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.2 to 17) · 124 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 638 cases | No different | Jan 2024 – Dec 2024 |
What patients said (666 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$667,251
Medicare paid this office $667,251 for 1,560 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 1,030 | $159,067 | $94 |
| Injection, denosumab, 1 mg | 22 | $84,096 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 188 | $43,178 | $196 |
| Short return visit (20+ min) | 473 | $38,773 | $68 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 41 | $35,870 | None |
See all 37 services
| Return visit (30+ min) | 1,030 | $159,067 | $94 |
| Injection, denosumab, 1 mg | 22 | $84,096 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 188 | $43,178 | $196 |
| Short return visit (20+ min) | 473 | $38,773 | $68 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 41 | $35,870 | None |
| New patient visit (45+ min) | 208 | $23,109 | $111 |
| Botox | 16 | $12,364 | None |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 667 | $10,683 | $13 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 31 | $10,508 | $318 |
| Short return visit | 179 | $8,864 | $41 |
| Biopsy of prostate gland | 42 | $7,494 | $178 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 16 | $7,425 | $337 |
| Insertion of lower leg neurostimulator electrode | 24 | $7,062 | $99 |
| Ultrasound scan of pelvic region through rectum | 60 | $7,046 | $117 |
| Ultrasound measurement of bladder capacity after voiding | 570 | $6,595 | $9 |
| Simple bladder irrigation and/or instillation | 35 | $5,344 | $57 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 12 | $3,827 | $319 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 14 | $3,655 | $261 |
| Simple insertion of temporary bladder tube | 48 | $3,394 | $47 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 34 | $3,291 | $91 |
| Insertion of device into abdomen with pressure and urine flow rate study | 17 | $2,879 | $169 |
| Simple change of bladder tube | 17 | $2,837 | $79 |
| Automated urinalysis test | 719 | $2,413 | $2 |
| Insertion of stent in ureter using an endoscope | 21 | $2,217 | $96 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 42 | $1,878 | $30 |
| Insertion of temporary bladder tube | 44 | $1,821 | $36 |
| Placement of device in prostate for radiation therapy | 12 | $1,459 | $122 |
| Pelvic exam | 47 | $1,223 | $19 |
| Injection of drug or substance under skin or into muscle | 67 | $1,170 | $12 |
| Imaging of urinary tract following injection of a contrast agent | 42 | $986 | $19 |
| Tissue marker, implantable, any type, each | 12 | $969 | $27 |
| New patient visit (30+ min) | 12 | $873 | $73 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $792 | $40 |
| Ultrasonic guidance for needle placement | 11 | $539 | $49 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 19 | $521 | $27 |
| Electronic assessment of bladder emptying | 16 | $108 | $7 |
| Injection, ceftriaxone sodium, per 250 mg | 41 | $17 | None |
Procedures Medicare counted
| Prostate resection | 13 | More than 64% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Ultrasound measurement of bladder capacity after voiding | 460 | 425 | 595 | 716 | 666 | 737 |
| Diagnostic exam of bladder and urethra using an endoscope | 174 | 166 | 203 | 201 | 221 | 220 |
| Simple insertion of temporary bladder tube | 69 | 73 | 137 | 94 | 106 | 72 |
| Insertion of lower leg neurostimulator electrode | 67 | 37 | 128 | 129 | 90 | 71 |
| Simple bladder irrigation and/or instillation | 21 | 35 | 84 | 95 | 89 | 93 |
| Insertion of temporary bladder tube | 14 | 27 | 35 | 90 | 65 | 50 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,560 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 15% · Women 31% · Also on Medicaid 31% · Health risk score 1.40. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Diabetes 35% · Chronic kidney disease 29% · Cancer 25% · Coronary heart disease 24% · Depression 21% · Atrial fibrillation 19% · Heart failure 15% · COPD 13% · Stroke 9% · Dementia 8%.
The office billed $1,712,479, Medicare allowed $890,773 and paid $667,251; for 23,610 services of 108 kinds; $234,423 of it was for drugs given in the office and $432,829 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,560 | 23,610 | 75 | 1.40 | $1,712,479 | $667,251 |
| 2023 | 1,611 | 19,096 | 75 | 1.38 | $1,591,598 | $581,671 |
| 2022 | 1,569 | 24,720 | 75 | 1.33 | $1,731,851 | $705,353 |
| 2021 | 1,305 | 11,242 | 75 | 1.33 | $1,267,721 | $502,930 |
| 2020 | 1,039 | 9,195 | 75 | 1.39 | $889,836 | $373,214 |
| 2019 | 1,033 | 7,110 | 75 | 1.36 | $832,672 | $338,563 |
| 2018 | 407 | 1,426 | 73 | 1.50 | $275,949 | $78,211 |
| 2017 | 87 | 234 | 64 | 2.23 | $125,676 | $16,445 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 39 services
| Return visit (30+ min) | 988 | $154,343 | $96 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 55 | $49,488 | None |
| Injection, denosumab, 1 mg | 15 | $46,739 | None |
| Short return visit (20+ min) | 536 | $45,756 | $68 |
| Diagnostic exam of bladder and urethra using an endoscope | 186 | $43,613 | $197 |
| New patient visit (45+ min) | 246 | $28,039 | $114 |
| Short return visit | 217 | $11,050 | $41 |
| Botox | 17 | $10,343 | None |
| Removal of stent in ureter through ureter with review by radiologist | 15 | $10,237 | $682 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 28 | $9,667 | $333 |
| Insertion of lower leg neurostimulator electrode | 30 | $8,088 | $90 |
| Biopsy of prostate gland | 41 | $7,988 | $195 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 17 | $6,723 | $336 |
| Ultrasound scan of pelvic region through rectum | 51 | $6,163 | $121 |
| Simple bladder irrigation and/or instillation | 42 | $5,774 | $65 |
| Ultrasound measurement of bladder capacity after voiding | 544 | $5,745 | $9 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 15 | $5,259 | $351 |
| Simple insertion of temporary bladder tube | 51 | $5,085 | $48 |
| Bcg live intravesical instillation, 1 mg | 17 | $5,036 | None |
| Insertion of device into abdomen with pressure and urine flow rate study | 24 | $4,247 | $177 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 15 | $4,106 | $274 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 39 | $4,019 | $103 |
| Instillation of anti-cancer drug into bladder | 17 | $3,605 | $72 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 58 | $2,942 | $29 |
| Simple change of bladder tube | 19 | $2,837 | $79 |
| Insertion of stent in ureter using an endoscope | 23 | $2,595 | $89 |
| Automated urinalysis test | 778 | $2,519 | $2 |
| Insertion of temporary bladder tube | 55 | $2,325 | $36 |
| New patient visit (30+ min) | 27 | $2,174 | $81 |
| Placement of device in prostate for radiation therapy | 11 | $1,387 | $126 |
| Injection of drug or substance under skin or into muscle | 61 | $886 | $12 |
| Imaging of urinary tract following injection of a contrast agent | 39 | $833 | $19 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $775 | $41 |
| Tissue marker, implantable, any type, each | 11 | $733 | $22 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 24 | $670 | $28 |
| Ultrasonic guidance for needle placement | 11 | $544 | $49 |
| Pessary, reusable, rubber, any type | 17 | $354 | $20 |
| Electronic assessment of bladder emptying | 15 | $96 | $6 |
| Injection, ceftriaxone sodium, per 250 mg | 41 | $19 | None |
2022: 36 services
| Return visit (30+ min) | 997 | $159,969 | $99 |
| Injection, denosumab, 1 mg | 21 | $63,730 | None |
| Short return visit (20+ min) | 534 | $47,314 | $70 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 50 | $44,573 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 171 | $42,865 | $213 |
| New patient visit (45+ min) | 284 | $34,000 | $120 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 36 | $13,118 | $345 |
| Insertion of lower leg neurostimulator electrode | 40 | $12,692 | $98 |
| Short return visit | 236 | $12,682 | $43 |
| Removal of stent in ureter through ureter with review by radiologist | 16 | $12,039 | $708 |
| Biopsy of prostate gland | 39 | $7,832 | $186 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 11 | $6,679 | $607 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 22 | $6,324 | $275 |
| Bcg live intravesical instillation, 1 mg | 21 | $6,248 | None |
| Ultrasound measurement of bladder capacity after voiding | 556 | $6,080 | $8 |
| Simple bladder irrigation and/or instillation | 43 | $5,876 | $62 |
| Ultrasound scan of pelvic region through rectum | 41 | $5,389 | $122 |
| Simple insertion of temporary bladder tube | 50 | $4,747 | $50 |
| Instillation of anti-cancer drug into bladder | 22 | $4,534 | $77 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 11 | $3,613 | $328 |
| Insertion of temporary bladder tube | 67 | $3,510 | $39 |
| Dilation of urethra using an endoscope | 11 | $3,444 | $287 |
| Simple change of bladder tube | 21 | $3,116 | $74 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 11 | $3,088 | $238 |
| Insertion of stent in ureter using an endoscope | 24 | $3,008 | $111 |
| Automated urinalysis test | 810 | $2,779 | $2 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 54 | $2,386 | $28 |
| Insertion of device into abdomen with pressure and urine flow rate study | 11 | $2,048 | $186 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,013 | $112 |
| New patient visit (30+ min) | 17 | $1,453 | $85 |
| Imaging of urinary tract following injection of a contrast agent | 47 | $1,083 | $20 |
| Injection of drug or substance under skin or into muscle | 51 | $847 | $12 |
| Pessary, reusable, rubber, any type | 17 | $424 | $19 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 11 | $314 | $29 |
| Electronic assessment of bladder emptying | 11 | $67 | $6 |
| Injection, ceftriaxone sodium, per 250 mg | 24 | $10 | None |
2021: 29 services
| Return visit (30+ min) | 726 | $126,942 | $103 |
| Short return visit (20+ min) | 579 | $50,487 | $68 |
| Injection, denosumab, 1 mg | 14 | $41,052 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 181 | $40,583 | $200 |
| New patient visit (45+ min) | 293 | $36,422 | $124 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 37 | $32,430 | None |
| Insertion of lower leg neurostimulator electrode | 35 | $14,032 | $110 |
| Short return visit | 159 | $9,335 | $46 |
| Simple insertion of temporary bladder tube | 59 | $6,886 | $50 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 16 | $6,655 | $350 |
| Shock wave crushing of kidney stones | 11 | $6,129 | $557 |
| Biopsy of prostate gland | 28 | $5,787 | $207 |
| Simple bladder irrigation and/or instillation | 41 | $5,502 | $66 |
| Ultrasound measurement of bladder capacity after voiding | 448 | $5,181 | $9 |
| Simple change of bladder tube | 15 | $4,416 | $79 |
| Dilation of urethra using an endoscope | 14 | $4,157 | $297 |
| Ultrasound scan of pelvic region through rectum | 31 | $3,832 | $124 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $2,965 | $114 |
| New patient visit (30+ min) | 33 | $2,921 | $89 |
| Automated urinalysis test | 687 | $2,415 | $2 |
| Bcg live intravesical instillation, 1 mg | 11 | $2,224 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 37 | $1,937 | $28 |
| Insertion of stent in ureter using an endoscope | 16 | $1,635 | $96 |
| Instillation of anti-cancer drug into bladder | 11 | $1,605 | $80 |
| Insertion of temporary bladder tube | 33 | $1,324 | $38 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,013 | $84 |
| Imaging of urinary tract following injection of a contrast agent | 24 | $554 | $21 |
| Injection of drug or substance under skin or into muscle | 35 | $533 | $12 |
| Injection, ceftriaxone sodium, per 250 mg | 21 | $10 | None |
2020: 28 services
| Short return visit (20+ min) | 697 | $63,527 | $57 |
| Return visit (30+ min) | 403 | $57,287 | $84 |
| New patient visit (45+ min) | 284 | $33,915 | $119 |
| Diagnostic exam of bladder and urethra using an endoscope | 138 | $28,411 | $171 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $27,277 | None |
| Crushing of stone of ureter with insertion of stent using an endoscope | 17 | $6,069 | $337 |
| Biopsy of prostate gland | 21 | $4,159 | $198 |
| Insertion of lower leg neurostimulator electrode | 16 | $3,676 | $99 |
| Ultrasound measurement of bladder capacity after voiding | 333 | $3,577 | $8 |
| Simple change of bladder tube | 14 | $3,406 | $81 |
| Simple insertion of temporary bladder tube | 37 | $3,324 | $46 |
| Ultrasound scan of pelvic region through rectum | 25 | $3,034 | $121 |
| Simple bladder irrigation and/or instillation | 27 | $2,186 | $62 |
| Automated urinalysis test | 553 | $1,938 | $2 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,836 | $115 |
| Insertion of device into abdomen with pressure and urine flow rate study | 11 | $1,752 | $146 |
| Insertion of stent in ureter using an endoscope | 16 | $1,710 | $95 |
| New patient visit (30+ min) | 14 | $1,130 | $81 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $1,061 | $27 |
| Insertion of temporary bladder tube | 26 | $899 | $33 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $877 | $63 |
| Imaging of urinary tract following injection of a contrast agent | 25 | $606 | $22 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 14 | $439 | $29 |
| Injection of drug or substance under skin or into muscle | 24 | $331 | $11 |
| Psa (prostate specific antigen) measurement, complexed | 16 | $270 | $17 |
| Electronic assessment of bladder emptying | 11 | $74 | $6 |
| Insertion of needle into vein for collection of blood sample | 16 | $44 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 12 | $6 | None |
2019: 34 services
| Short return visit (20+ min) | 700 | $73,413 | $57 |
| New patient visit (45+ min) | 316 | $38,330 | $121 |
| Return visit (30+ min) | 284 | $36,974 | $86 |
| Diagnostic exam of bladder and urethra using an endoscope | 156 | $26,742 | $154 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $15,465 | None |
| Insertion of lower leg neurostimulator electrode | 28 | $6,934 | $103 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 19 | $6,280 | $314 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 18 | $6,047 | $336 |
| Ultrasound measurement of bladder capacity after voiding | 340 | $4,772 | $10 |
| New patient visit (30+ min) | 59 | $4,249 | $72 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 16 | $4,030 | $224 |
| Simple insertion of temporary bladder tube | 34 | $3,577 | $52 |
| Biopsy of prostate gland | 17 | $3,513 | $207 |
| Insertion of device into abdomen with pressure and urine flow rate study | 27 | $3,420 | $122 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 11 | $2,882 | $240 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 12 | $2,882 | $206 |
| Automated urinalysis test | 565 | $2,314 | $2 |
| Simple change of bladder tube | 19 | $2,286 | $71 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,234 | $112 |
| Psa (prostate specific antigen) measurement, complexed | 71 | $2,023 | $20 |
| Insertion of stent in ureter using an endoscope | 17 | $1,698 | $94 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 13 | $1,263 | $34 |
| Simple bladder irrigation and/or instillation | 16 | $1,212 | $58 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 32 | $930 | $28 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $675 | $32 |
| Ultrasonic guidance for needle placement | 13 | $665 | $48 |
| Injection of drug or substance under skin or into muscle | 32 | $664 | $13 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $657 | $25 |
| Imaging of urinary tract following injection of a contrast agent | 25 | $586 | $21 |
| Insertion of temporary bladder tube | 14 | $533 | $38 |
| Insertion of needle into vein for collection of blood sample | 73 | $303 | $3 |
| Electronic assessment of bladder emptying | 21 | $129 | $6 |
| Catheterization for collection of specimen, single patient, all places of service | 15 | $44 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 17 | $7 | None |
2018: 14 services
| New patient visit (45+ min) | 106 | $14,004 | $132 |
| Short return visit (20+ min) | 168 | $12,864 | $60 |
| Return visit (30+ min) | 67 | $6,679 | $89 |
| Diagnostic exam of bladder and urethra using an endoscope | 31 | $4,512 | $141 |
| New patient visit (30+ min) | 49 | $4,276 | $87 |
| Insertion of stent in ureter using an endoscope | 12 | $1,807 | $129 |
| Short return visit (20+ min) | 37 | $1,732 | $38 |
| Ultrasound measurement of bladder capacity after voiding | 113 | $1,694 | $14 |
| Automated urinalysis test | 169 | $589 | $3 |
| Diagnostic exam of bladder and urethra using an endoscope | 12 | $508 | $42 |
| Psa (prostate specific antigen) measurement, complexed | 17 | $378 | $22 |
| Short return visit | 19 | $328 | $16 |
| Imaging of urinary tract following injection of a contrast agent | 11 | $166 | $14 |
| Insertion of needle into vein for collection of blood sample | 18 | $53 | $3 |
2017: 4 services
| Short return visit (20+ min) | 40 | $2,284 | $41 |
| Diagnostic exam of bladder and urethra using an endoscope | 20 | $1,379 | $69 |
| Return visit (30+ min) | 14 | $944 | $63 |
| Short return visit | 14 | $347 | $20 |
Medicaid work
$79,164 in 2024
Medicaid paid $79,164 for 1,905 billed services this clinician did in 2024, up to 105 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 543 | $33,757 |
| New patient visit (45+ min) | 146 | $19,309 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 229 | $11,668 |
| Short return visit (20+ min) | 175 | $7,331 |
| CYSTOURETHROSCOPY | 42 | $3,666 |
| Short return visit | 82 | $2,172 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 445 | $846 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 73 | $346 |
| Service | 121 | $65 |
| Service | 49 | $5 |
| 2024 | 1,905 | 10 | 105 | $79,164 |
| 2023 | 3,496 | 9 | 110 | $100,986 |
| 2022 | 3,115 | 10 | 94 | $129,388 |
| 2021 | 2,715 | 7 | 75 | $128,949 |
| 2020 | 1,755 | 5 | 62 | $76,493 |
| 2019 | 869 | 5 | 43 | $21,588 |
| 2018 | 190 | 3 | 22 | $4,552 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 997 | $39,355 |
| New patient visit (45+ min) | 321 | $26,861 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 382 | $13,598 |
| Short return visit (20+ min) | 386 | $10,764 |
| CYSTOURETHROSCOPY | 86 | $6,011 |
| Short return visit | 156 | $3,011 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 836 | $1,200 |
| Service | 218 | $187 |
| Service | 114 | $0 |
2022
| Return visit (30+ min) | 916 | $56,668 |
| New patient visit (45+ min) | 276 | $32,959 |
| Short return visit (20+ min) | 369 | $17,889 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 399 | $14,507 |
| Short return visit | 149 | $4,449 |
| CYSTOURETHROSCOPY | 26 | $1,690 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 813 | $1,022 |
| Service | 29 | $105 |
| Service | 86 | $96 |
| Service | 52 | $2 |
2021
| Return visit (30+ min) | 676 | $43,535 |
| New patient visit (45+ min) | 326 | $42,249 |
| Short return visit (20+ min) | 436 | $20,890 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 360 | $14,880 |
| CYSTOURETHROSCOPY | 53 | $3,355 |
| Short return visit | 99 | $2,895 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 765 | $1,146 |
2020
| New patient visit (45+ min) | 278 | $32,596 |
| Short return visit (20+ min) | 509 | $19,746 |
| Return visit (30+ min) | 302 | $17,396 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 161 | $5,935 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 505 | $820 |
2019
| Short return visit (20+ min) | 360 | $14,092 |
| New patient visit (45+ min) | 45 | $3,299 |
| Return visit (30+ min) | 50 | $2,148 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 36 | $1,256 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 378 | $793 |
2018
| Short return visit (20+ min) | 78 | $3,056 |
| New patient visit (45+ min) | 13 | $1,017 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 99 | $479 |
Drugs they prescribed that Part D paid
$1,733,371
Pharmacies billed $1,733,371 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (67 of 2,693) in 2024. Above the middle of the specialty; the typical urology clinician is at 2%.
2,278 generic and fewer than 11 brand-name prescriptions · $1,733,371 in drug cost · 273 antibiotic prescriptions to 160 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 96 | $1,290,387 | $13,442 |
| Gemtesa | 151 | $174,560 | $1,156 |
| Myrbetriq | 130 | $129,536 | $996 |
| Abiraterone Acetate | 20 | $57,322 | $2,866 |
| Tamsulosin | 927 | $15,855 | $17 |
See all 29 drugs
| Xtandi | 96 | $1,290,387 | $13,442 |
| Gemtesa | 151 | $174,560 | $1,156 |
| Myrbetriq | 130 | $129,536 | $996 |
| Abiraterone Acetate | 20 | $57,322 | $2,866 |
| Tamsulosin | 927 | $15,855 | $17 |
| Elmiron | 11 | $10,219 | $929 |
| Testosterone | 43 | $7,446 | $173 |
| Finasteride | 479 | $7,076 | $15 |
| Estradiol | 56 | $3,071 | $55 |
| Potassium Citrate Er | 41 | $3,012 | $73 |
| Methenamine Hippurate | 28 | $2,989 | $107 |
| Alfuzosin Hcl Er | 109 | $2,398 | $22 |
| Dutasteride | 34 | $1,310 | $39 |
| Oxybutynin Chloride Er | 29 | $1,207 | $42 |
| Solifenacin | 24 | $1,169 | $49 |
| Nitrofurantoin | 21 | $734 | $35 |
| Cefdinir | 52 | $661 | $13 |
| Clotrimazole | 25 | $550 | $22 |
| Nitrofurantoin Mono-Macro | 33 | $448 | $14 |
| Hydroxyzine | 16 | $436 | $27 |
| Betamethasone Dipropionate | 12 | $432 | $36 |
| Levofloxacin | 91 | $242 | $3 |
| Amoxicillin-Clavulanate Potass | 20 | $156 | $8 |
| Hydrocodone-Acetaminophen | 23 | $144 | $6 |
| Cephalexin | 17 | $125 | $7 |
| Sulfamethoxazole-Trimethoprim | 25 | $105 | $4 |
| Prednisone | 21 | $58 | $3 |
| Tramadol | 41 | $54 | $1 |
| Fluconazole | 12 | $48 | $4 |
Year by year
| 2024 | 2,693 | 752 | 3% (67) | None | $1,733,371 |
| 2023 | 2,621 | 751 | 2% (56) | None | $1,266,225 |
| 2022 | 2,682 | 761 | 2% (52) | None | $520,538 |
| 2021 | 2,342 | 615 | 1% (33) | None | $453,823 |
| 2020 | 1,941 | 489 | 2% (38) | None | $301,294 |
| 2019 | 1,368 | 381 | 3% (39) | None | $398,464 |
| 2018 | 331 | 136 | None | 19% | $35,044 |
| 2017 | 93 | 43 | None | 22% | $8,161 |
| 2016 | 45 | 26 | 44% (20) | None | $743 |
| 2015 | 84 | 54 | 44% (37) | None | $1,282 |
| 2014 | 85 | 35 | None | None | $2,694 |
| 2013 | 33 | 23 | 0% (0) | None | $3,319 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 25 drugs
| Xtandi | 62 | $910,710 | $14,689 |
| Gemtesa | 103 | $122,609 | $1,190 |
| Myrbetriq | 119 | $117,138 | $984 |
| Tamsulosin | 863 | $26,780 | $31 |
| Finasteride | 540 | $13,636 | $25 |
| Testosterone | 27 | $10,953 | $406 |
| Estradiol | 83 | $9,213 | $111 |
| Solifenacin | 62 | $7,445 | $120 |
| Potassium Citrate Er | 39 | $5,445 | $140 |
| Alfuzosin Hcl Er | 122 | $5,244 | $43 |
| Oxybutynin Chloride Er | 75 | $4,307 | $57 |
| Methenamine Hippurate | 36 | $3,952 | $110 |
| Dutasteride | 37 | $2,468 | $67 |
| Cephalexin | 40 | $1,151 | $29 |
| Nitrofurantoin | 16 | $775 | $48 |
| Nitrofurantoin Mono-Macro | 31 | $650 | $21 |
| Hydroxyzine | 25 | $582 | $23 |
| Cefdinir | 26 | $567 | $22 |
| Levofloxacin | 83 | $371 | $4 |
| Terazosin | 13 | $230 | $18 |
| Clotrimazole | 11 | $181 | $16 |
| Amoxicillin-Clavulanate Potass | 14 | $162 | $12 |
| Sulfamethoxazole-Trimethoprim | 35 | $138 | $4 |
| Hydrocodone-Acetaminophen | 20 | $115 | $6 |
| Tramadol | 33 | $64 | $2 |
2022: 30 drugs
| Myrbetriq | 223 | $204,753 | $918 |
| Xtandi | 14 | $185,438 | $13,246 |
| Gemtesa | 22 | $24,312 | $1,105 |
| Tamsulosin | 797 | $18,925 | $24 |
| Toviaz | 11 | $12,281 | $1,116 |
| Finasteride | 529 | $10,527 | $20 |
| Testosterone | 30 | $8,840 | $295 |
| Solifenacin | 86 | $8,606 | $100 |
| Oxybutynin Chloride Er | 123 | $8,585 | $70 |
| Estradiol | 64 | $7,825 | $122 |
| Potassium Citrate Er | 33 | $4,505 | $137 |
| Dutasteride | 43 | $3,333 | $78 |
| Methenamine Hippurate | 31 | $2,685 | $87 |
| Alfuzosin Hcl Er | 89 | $2,669 | $30 |
| Nitrofurantoin | 26 | $2,581 | $99 |
| Cephalexin | 85 | $975 | $11 |
| Nitrofurantoin Mono-Macro | 51 | $825 | $16 |
| Cefdinir | 55 | $769 | $14 |
| Betamethasone Dipropionate | 15 | $733 | $49 |
| Clotrimazole-Betamethasone | 13 | $571 | $44 |
| Clotrimazole | 17 | $478 | $28 |
| Levofloxacin | 92 | $429 | $5 |
| Doxazosin Mesylate | 12 | $424 | $35 |
| Amoxicillin-Clavulanate Potass | 24 | $234 | $10 |
| Hydroxyzine | 16 | $156 | $10 |
| Hydrocodone-Acetaminophen | 26 | $136 | $5 |
| Sulfamethoxazole-Trimethoprim | 35 | $132 | $4 |
| Fluconazole | 12 | $109 | $9 |
| Tramadol | 22 | $41 | $2 |
| Ciprofloxacin | 11 | $33 | $3 |
2021: 23 drugs
| Myrbetriq | 260 | $188,870 | $726 |
| Xtandi | 19 | $185,795 | $9,779 |
| Tamsulosin | 719 | $14,755 | $21 |
| Toviaz | 11 | $11,857 | $1,078 |
| Finasteride | 417 | $9,318 | $22 |
| Estradiol | 42 | $6,104 | $145 |
| Oxybutynin Chloride Er | 88 | $5,127 | $58 |
| Solifenacin | 70 | $4,686 | $67 |
| Potassium Citrate Er | 36 | $3,953 | $110 |
| Dutasteride | 47 | $3,546 | $75 |
| Cefdinir | 46 | $994 | $22 |
| Nitrofurantoin | 13 | $961 | $74 |
| Alfuzosin Hcl Er | 56 | $934 | $17 |
| Cephalexin | 81 | $616 | $8 |
| Nitrofurantoin Mono-Macro | 23 | $483 | $21 |
| Levofloxacin | 68 | $300 | $4 |
| Atorvastatin | 12 | $177 | $15 |
| Hydroxyzine | 28 | $153 | $5 |
| Amoxicillin-Clavulanate Potass | 26 | $145 | $6 |
| Hydrocodone-Acetaminophen | 17 | $102 | $6 |
| Sulfamethoxazole-Trimethoprim | 25 | $74 | $3 |
| Amlodipine Besylate | 11 | $59 | $5 |
| Metoprolol | 12 | $58 | $5 |
2020: 26 drugs
| Xtandi | 15 | $114,938 | $7,663 |
| Myrbetriq | 171 | $110,373 | $645 |
| Toviaz | 23 | $20,840 | $906 |
| Tamsulosin | 598 | $11,653 | $19 |
| Finasteride | 310 | $6,705 | $22 |
| Estrace | 15 | $5,310 | $354 |
| Dutasteride | 63 | $3,777 | $60 |
| Oxybutynin Chloride Er | 78 | $2,777 | $36 |
| Potassium Citrate Er | 17 | $2,536 | $149 |
| Estradiol | 17 | $2,513 | $148 |
| Solifenacin | 30 | $2,478 | $83 |
| Alfuzosin Hcl Er | 52 | $1,207 | $23 |
| Cefdinir | 52 | $1,039 | $20 |
| Nitrofurantoin | 21 | $585 | $28 |
| Cephalexin | 75 | $534 | $7 |
| Nitrofurantoin Mono-Macro | 17 | $352 | $21 |
| Oxcarbazepine | 12 | $310 | $26 |
| Hydroxyzine | 16 | $231 | $14 |
| Levofloxacin | 41 | $179 | $4 |
| Lisinopril | 11 | $105 | $10 |
| Terazosin | 11 | $101 | $9 |
| Hydrocodone-Acetaminophen | 21 | $95 | $5 |
| Sulfamethoxazole-Trimethoprim | 30 | $95 | $3 |
| Amoxicillin-Clavulanate Potass | 12 | $85 | $7 |
| Ciprofloxacin | 11 | $83 | $8 |
| Amlodipine Besylate | 11 | $71 | $6 |
2019: 20 drugs
| Xtandi | 20 | $243,956 | $12,198 |
| Myrbetriq | 183 | $95,753 | $523 |
| Toviaz | 29 | $14,969 | $516 |
| Tamsulosin | 426 | $7,763 | $18 |
| Finasteride | 207 | $4,990 | $24 |
| Testosterone | 13 | $4,266 | $328 |
| Oxybutynin Chloride Er | 62 | $2,857 | $46 |
| Potassium Citrate Er | 16 | $2,213 | $138 |
| Solifenacin | 20 | $1,428 | $71 |
| Dutasteride | 21 | $1,087 | $52 |
| Cefdinir | 30 | $636 | $21 |
| Alfuzosin Hcl Er | 28 | $573 | $20 |
| Cephalexin | 24 | $294 | $12 |
| Terazosin | 12 | $242 | $20 |
| Nitrofurantoin Mono-Macro | 15 | $239 | $16 |
| Clotrimazole | 12 | $169 | $14 |
| Amoxicillin-Clavulanate Potass | 14 | $124 | $9 |
| Levofloxacin | 37 | $111 | $3 |
| Sulfamethoxazole-Trimethoprim | 30 | $107 | $4 |
| Hydrocodone-Acetaminophen | 21 | $103 | $5 |
2018: 5 drugs
| Myrbetriq | 26 | $15,647 | $602 |
| Vesicare | 17 | $6,035 | $355 |
| Tamsulosin | 100 | $2,402 | $24 |
| Oxybutynin Chloride Er | 27 | $989 | $37 |
| Finasteride | 41 | $911 | $22 |
2017: 1 drug
| Tamsulosin | 19 | $413 | $22 |
2016: 1 drug
| Oxycodone | 11 | $96 | $9 |
2015: 2 drugs
| Tamsulosin | 17 | $244 | $14 |
| Hydrocodone-Acetaminophen | 19 | $146 | $8 |
2014: 2 drugs
| Tamsulosin | 20 | $330 | $17 |
| Carvedilol | 12 | $65 | $5 |
2013: 1 drug
| Ciprofloxacin | 12 | $63 | $5 |
Money from drug and device companies
$1,506 in 2025
| 2025 | 24 | 58 | None | $1,506 |
| 2024 | 19 | 38 | None | $807 |
| 2023 | 19 | 50 | None | $1,481 |
| 2022 | 18 | 47 | None | $1,279 |
| 2021 | 13 | 31 | None | $820 |
| 2020 | 9 | 14 | None | $421 |
| 2019 | 11 | 15 | None | $298 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ferring Pharmaceuticals | Adstiladrin | $214 | 6 payments
|
| Novartis Pharmaceuticals | Pluvicto | $163 | 8 payments
|
| Abbvie | Botox | $152 | 7 payments
|
| Procept Biorobotics | Aquabeam Robotic System | $118 | 1 payment
|
| Pfizer | Xtandi | $82 | 3 payments
|
| Bluewind Medical | Revi | $73 | 3 payments
|
See all 58 published payments
| Urogen Pharma | Meals · 2025-12-16 | Jelmyto | $24 |
| Abbvie | Meals · 2025-12-10 | Botox | $33 |
| Ferring Pharmaceuticals | Meals · 2025-12-10 | Adstiladrin | $31 |
| Progenics Pharmaceuticals | Meals · 2025-11-21 | Pylarify | $29 |
| Dendreon Pharmaceuticals | Meals · 2025-11-11 | Provenge | $18 |
| Abbvie | Meals · 2025-10-30 | Botox | $20 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-29 | Nubeqa | $15 |
| Ferring Pharmaceuticals | Meals · 2025-10-28 | Adstiladrin | $32 |
| Astellas Pharma US | Meals · 2025-10-08 | Xtandi | $19 |
| Accord Healthcare | Meals · 2025-10-08 | Camcevi | $30 |
| Sumitomo Pharma America | Meals · 2025-10-03 | Gemtesa | $15 |
| Cook Medical | Meals · 2025-09-30 | Resonance | $20 |
| Abbvie | Meals · 2025-09-18 | Lupron Depot | $17 |
| Urogen Pharma | Meals · 2025-09-16 | Zusduri | $21 |
| Novartis Pharmaceuticals | Meals · 2025-09-15 | Pluvicto | $28 |
| Janssen Biotech | Meals · 2025-09-10 | Rybrevant | $31 |
| Ferring Pharmaceuticals | Meals · 2025-09-09 | Adstiladrin | $33 |
| Teleflex | Meals · 2025-09-03 | Urolift | $26 |
| Astellas Pharma US | Meals · 2025-08-26 | Xtandi | $26 |
| Merck Sharp & Dohme | Education · 2025-08-21 | Lynparza | $26 |
| Sumitomo Pharma America | Meals · 2025-08-19 | Gemtesa | $17 |
| Dendreon Pharmaceuticals | Meals · 2025-08-13 | Provenge | $29 |
| Novartis Pharmaceuticals | Meals · 2025-08-07 | Pluvicto | $25 |
| Novartis Pharmaceuticals | Meals · 2025-08-07 | Pluvicto | $3 |
| Bluewind Medical | Meals · 2025-08-06 | Revi | $20 |
| Teleflex | Meals · 2025-08-06 | Urolift | $32 |
| Janssen Biotech | Meals · 2025-08-05 | Erleada | $29 |
| Novartis Pharmaceuticals | Meals · 2025-07-22 | Pluvicto | $24 |
| Verity Pharmaceuticals | Meals · 2025-07-22 | Tlando | $24 |
| Ferring Pharmaceuticals | Meals · 2025-07-08 | Adstiladrin | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-19 | Lynparza | $20 |
| Pfizer | Meals · 2025-06-11 | Xtandi | $30 |
| Novartis Pharmaceuticals | Meals · 2025-06-04 | Pluvicto | $31 |
| Abbvie | Meals · 2025-05-14 | Lupron Depot | $22 |
| Pfizer | Meals · 2025-05-14 | Xtandi | $26 |
| Ferring Pharmaceuticals | Meals · 2025-05-09 | Adstiladrin | $35 |
| Ferring Pharmaceuticals | Meals · 2025-05-07 | Adstiladrin | $51 |
| Verity Pharmaceuticals | Meals · 2025-05-01 | Tlando | $21 |
| Novartis Pharmaceuticals | Meals · 2025-04-30 | Pluvicto | $30 |
| Novartis Pharmaceuticals | Meals · 2025-04-30 | Pluvicto | $6 |
| Antares Pharma | Meals · 2025-04-28 | Xyosted | $23 |
| Novartis Pharmaceuticals | Meals · 2025-04-18 | Pluvicto | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-17 | Lynparza | $19 |
| Boston Scientific | Meals · 2025-04-15 | Ams 700 | $43 |
| Abbvie | Meals · 2025-04-07 | Lupron Depot | $25 |
| Astellas Pharma US | Meals · 2025-04-01 | Xtandi | $16 |
| Abbvie | Meals · 2025-03-26 | Botox | $31 |
| Cook Medical | Meals · 2025-03-20 | Ncircle | $28 |
| Procept Biorobotics | Meals · 2025-03-11 | Aquabeam Robotic System | $118 |
| Bluewind Medical | Meals · 2025-03-10 | Revi | $28 |
| Bluewind Medical | Meals · 2025-03-07 | Revi | $25 |
| Pfizer | Meals · 2025-02-27 | Xtandi | $25 |
| Sumitomo Pharma America | Meals · 2025-02-25 | Orgovyx | $27 |
| Abbvie | Meals · 2025-02-20 | Lupron Depot | $4 |
| Myriad Genetic Laboratories | Meals · 2025-02-18 | Prolaris | $21 |
| Coloplast | Meals · 2025-02-10 | Titan | $16 |
| Tolmar | Meals · 2025-02-10 | Jatenzo | $19 |
| Coloplast | Meals · 2025-02-04 | Titan | $23 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $807
| Abbvie | Lupron Depot | $149 | 7 payments
|
| Astellas Pharma US | Xtandi | $86 | 4 payments
|
| Sumitomo Pharma America | Gemtesa | $78 | 4 payments
|
| Pfizer | Xtandi | $77 | 3 payments
|
| Novartis Pharmaceuticals | Pluvicto | $62 | 2 payments
|
| Amgen | Prolia | $41 | 2 payments
|
| Antares Pharma | Xyosted | $34 | 2 payments
|
| Myriad Genetic Laboratories | Prolaris | $33 | 2 payments
|
| Sun Pharmaceutical Industries | Yonsa | $33 | 1 payment
|
| Axonics | Axonics | $30 | 2 payments
|
| Boston Scientific | Ams 800 Artificial Urinary Sphincter | $29 | 1 payment
|
| Becton Dickinson and | Bard Urinary Drainage Bag | $23 | 1 payment
|
| Verity Pharmaceuticals | Trelstar | $22 | 1 payment
|
| Accord Healthcare | Camcevi | $20 | 1 payment
|
| Dendreon Pharmaceuticals | Provenge | $20 | 1 payment
|
| Urogen Pharma | Jelmyto | $20 | 1 payment
|
| Endo Pharmaceuticals | Xiaflex | $18 | 1 payment
|
| Endo USA | Xiaflex | $16 | 1 payment
|
| Ferring Pharmaceuticals | Adstiladrin | $15 | 1 payment
|
2023: $1,481
| Myriad Genetic Laboratories | Myrisk | $371 | 7 payments
|
| Sumitomo Pharma America | Gemtesa | $230 | 11 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $127 | 1 payment
|
| Pfizer | Xtandi | $120 | 5 payments
|
| Laborie Medical Technologies | None | $95 | 1 payment
|
| Tolmar | Eligard | $90 | 4 payments
|
| Antares Pharma | Nocdurna | $53 | 2 payments
|
| Astellas Pharma US | Myrbetriq | $53 | 3 payments
|
| Boston Scientific | Advance Xp | $49 | 1 payment
|
| Supernus Pharmaceuticals | Xyosted | $49 | 2 payments
|
| AbbVie | Botox | $44 | 2 payments
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $43 | 2 payments
|
| Endo Pharmaceuticals | Xiaflex | $42 | 2 payments
|
| Janssen Biotech | Erleada | $35 | 2 payments
|
| AngioDynamics | Nanoknife | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $19 | 1 payment
|
| UroGen Pharma | None | $15 | 1 payment
|
| Coloplast | Titan | $14 | 1 payment
|
| Amgen | Prolia | $13 | 1 payment
|
2022: $1,279
| Astellas Pharma US | Myrbetriq | $222 | 4 payments
|
| Abbvie | Botox | $178 | 12 payments
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $134 | 1 payment
|
| Boston Scientific | Advance Xp | $133 | 1 payment
|
| Urovant Sciences | Gemtesa | $119 | 8 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $70 | 1 payment
|
| TOLMAR Pharmaceuticals | Eligard | $69 | 4 payments
|
| Axonics | Axonics | $62 | 3 payments
|
| Blue Earth Diagnostics | Axumin | $54 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $41 | 2 payments
|
| Palette Life Sciences | None | $38 | 2 payments
|
| Ethicon US | Enseal | $31 | 1 payment
|
| Myovant Sciences | Orgovyx | $27 | 1 payment
|
| Olympus America | Itind System | $25 | 1 payment
|
| Philips Electronics North America | (4504) Uronav Add on | $23 | 1 payment
|
| Coloplast | Titan | $22 | 1 payment
|
| UroGen Pharma | Jelmyto | $16 | 1 payment
|
| Allergan | Botox | $12 | 1 payment
|
2021: $820
| Astellas Pharma US | Xtandi | $169 | 5 payments
|
| Sanara MedTech | Celleraterx | $156 | 1 payment
|
| Amgen | Xgeva | $98 | 4 payments
|
| AbbVie | Lupron Depot | $72 | 4 payments
|
| Allergan | Botox | $51 | 3 payments
|
| Pfizer | Premarin | $44 | 2 payments
|
| TOLMAR Pharmaceuticals | Eligard | $44 | 2 payments
|
| Myovant Sciences | Orgovyx | $43 | 3 payments
|
| Myriad Genetic Laboratories | Prolaris | $42 | 2 payments
|
| Janssen Biotech | Erleada | $33 | 2 payments
|
| Boston Scientific | Lithovue | $28 | 1 payment
|
| Coloplast | Titan | $23 | 1 payment
|
| Medtronic | Signia | $19 | 1 payment
|
2020: $421
| Astellas Pharma US | Myrbetriq | $203 | 5 payments
|
| NeoTract | Urolift | $93 | 1 payment
|
| Janssen Biotech | Erleada | $37 | 2 payments
|
| Dendreon Pharmaceuticals | Provenge | $16 | 1 payment
|
| Pfizer | Toviaz | $15 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $15 | 1 payment
|
| Dentsply Ih | Lofric | $14 | 1 payment
|
| Coloplast | Penile & Testicular Reconstructn | $14 | 1 payment
|
| Endo Pharmaceuticals | Aveed | $14 | 1 payment
|
2019: $298
| Photocure | Cysview | $55 | 1 payment
|
| Medtronic USA | Interstim | $43 | 2 payments
|
| Pfizer | Xtandi | $43 | 3 payments
|
| Janssen Biotech | Erleada | $27 | 2 payments
|
| Dendreon Pharmaceuticals | Provenge | $25 | 1 payment
|
| Allergan | Botox | $22 | 1 payment
|
| AbbVie | Lupron Depot | $22 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Xofigo | $18 | 1 payment
|
| TherapeuticsMD | Imvexxy | $16 | 1 payment
|
| Metuchen Pharmaceuticals | Stendra | $14 | 1 payment
|
| Coloplast | Titan | $13 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 87.7 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1013273036
- Licence
- CO DR.0058294Colorado DR.58294: Expired
- Trained
- University of Miami, Lm Miller School of Medicine, 2012 · 14 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 225 Prado Rd Ste D, San Luis Obispo, CA, 93401
- NPI first listed
- 2012-04-03
- NPI last updated
- 2026-09-11
- NPI record certified
- 2026-09-11
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 9200 W Wisconsin Ave, Milwaukee, WI, 53226